Jaideep Dudani

Jaideep Dudani is a Portfolio Principal at Monograph and leads Portfolio Development at Monograph’s portfolio company, Hi-Bio.
He was most recently at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy and business development.
Before that, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene Therapeutics (which held its initial public offering on the NASDAQ Global Select Market in 2018), Asklepios BioPharmaceutical (which was acquired by Bayer AG in 2020), Oyster Point Pharma (which held its initial public offering on the NASDAQ Global Select Market in 2019), and Pionyr Immunotherapeutics (which was acquired by Gilead Sciences, Inc. in 2020).
He completed his PhD at MIT in Biological Engineering, and holds a BS in Bioengineering from UCLA.